Bridgepoint buys Obagi Medical from Waldencast
The medical-grade skincare brand sells prescription and non-prescription products through dermatologists, aesthetic practitioners and healthcare professionals across North America, Europe, Asia and the Middle East.
Waldencast agreed to sell Obagi Medical, its dermatological skincare and aesthetics business offering prescription and non-prescription products for skin aging and discoloration, to Bridgepoint.
The brand operates across North America, Europe, Asia and the Middle East through dermatologists, aesthetic practitioners and other healthcare professionals.
The transaction carries an enterprise value of up to $460 million, subject to adjustments for net financial indebtedness, working-capital variations, debt-like items and contingent future payments.
Bridgepoint will acquire 100% of the equity interests, and the deal is not subject to a financing condition or shareholder vote.
Founded in 1988, Obagi Medical added Novaestiq in 2025, and that deal led to the Q1 2026 launch of the FDA-approved Obagi Saypha® MagIQ™ dermal filler line.
Waldencast founders Michel Brousset and Hind Sebti, along with selected management members, are expected to transition to Obagi Medical at closing.